Loading data for NAMSW — first visit, this takes a few seconds.
NewAmsterdam Pharma N.V. (NAMSW)
NasdaqGM: NAMSW
· Precio en tiempo real · USD
16.00
+0.00 (0.00%)
Al cierre: Aug 18, 2026, 2:21 PM
NewAmsterdam Pharma N.V. (NAMSW) Stock Price, Analysis & Data
0.00% (1D)
| Precio de compra | n/a |
| Capitalización de mercado | n/a |
| Ingresos (TTM) | 7.12M |
| Beneficio neto (TTM) | -259.5M |
| Beta | 0.11 |
| EPS (TTM) | n/a |
| Ratio PER (TTM) | n/a |
| Adelante PE | n/a |
| P/B (TTM) | 2.98 |
| P/S (TTM) | n/a |
| Earnings Date | n/a |
| Precio de venta | n/a |
| Volumen | 15,005 |
| Volumen medio (20D) | 1,246 |
| Abierto | 24.41 |
| Anterior Cerrar | 16.00 |
| Rango del día | 15.98 - 16.00 |
| Rango de 52 semanas | 12.67 - 30.45 |
| analista | n/a |
| Precio objetivo | n/a |
| Dividendos | n/a |
| Fecha ex dividendo | n/a |
Acerca de NAMSW
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is ...
IPO Fecha Feb 10, 2021
Empleados 100
Bolsa de Valores NasdaqGM
Símbolo bursátil NAMSW
Sitio web https://www.newamsterdampharma.com
Desempeño financiero
En 2025, los ingresos de NewAmsterdam Pharma fueron 22.5M, una disminución de -50.61% en comparación con 45.56M del año anterior. Las ganancias fueron -203.82M, una disminución de -15.64%.
Estados financieros